New Descriptor for Glomerulus Detection in Kidney Microscopy Image

Glomerulus detection is a key step in histopathological evaluation of microscopy images of kidneys. However, the task of automatic detection of glomeruli poses challenges due to the disparity in sizes and shapes of glomeruli in renal sections. Moreover, extensive variations of their intensities due to heterogeneity in immunohistochemistry staining are also encountered. Despite being widely recognized as a powerful descriptor for general object detection, the rectangular histogram of oriented gradients (Rectangular HOG) suffers from many false positives due to the aforementioned difficulties in the context of glomerulus detection. A new descriptor referred to as Segmental HOG is developed to perform a comprehensive detection of hundreds of glomeruli in images of whole kidney sections. The new descriptor possesses flexible blocks that can be adaptively fitted to input images to acquire robustness to deformations of glomeruli. Moreover, the novel segmentation technique employed herewith generates high quality segmentation outputs and the algorithm is assured to converge to an optimal solution. Consequently, experiments using real world image data reveal that Segmental HOG achieves significant improvements in detection performance compared to Rectangular HOG. The proposed descriptor and method for glomeruli detection present promising results and is expected to be useful in pathological evaluation

Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models

Amiselimod (MT-1303) is a novel and selective sphingosine 1-phosphate receptor-1 (S1P1) modulator with a more favorable cardiac safety profile than other S1P1 receptor modulators. In this study, we evaluated the effects of MT-1303 on the progression of lupus nephritis in two well-known murine systemic lupus erythematosus (SLE) models, MRL/lpr and NZBWF1 mice, compared with those of FK506. Daily oral doses of 0.1 and 0.3 mg/kg MT-1303 not only inhibited the development of lupus nephritis when administered before onset in MRL/lpr and NZBWF1 mice but also improved symptoms of lupus nephritis when administered after onset in MRL/lpr mice. Its efficacy in these models was more potent or comparable to that of FK506 (1 and 3 mg/kg). In histological analysis, treatment with MT-1303 inhibited infiltration of T cells into the kidneys, mesangial expansion, and glomerular sclerosis. MT-1303 treatment resulted in a marked reduction in T cells and B cells in the peripheral blood and significantly inhibited increases in the number of plasma cells in the spleen and T cells in the kidneys. In addition, administration of MT-1303 suppressed elevations in serum anti-dsDNA antibody levels in MRL/lpr mice, but not in NZBWF1 mice. Our findings show that MT-1303 exhibits marked therapeutic effects on lupus nephritis in two SLE models, likely by reducing the infiltration of autoreactive T cells into the kidneys. These results suggest that MT-1303 has the potential to be used as a therapeutic agent for patients suffering from SLE, including lupus nephritis